GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - REZOLUTE INC

Financial Performance:

• No specific Q3 revenue, earnings, or cash flow figures were disclosed for the current period.
• Current cash position is approximately $90 million, deemed sufficient for ongoing operations but insufficient to fund a full commercial launch of multiple indications.
• Company anticipates a need for future capital raises to support commercial ramp-up.
• No data provided on debt, deferred revenue, or profit margins.

Guidance and Future Outlook:

• Plans to submit a Biologics License Application (BLA) for the congenital hyperinsulinism (CHI) indication in the middle of next year.
• Conservative commercialization timeline projects a Pediatric Review Committee (Ped-FoR) meeting for CHI in Q1 2028, followed by a supplemental BLA (sBLA) filing for the tumor indication approximately nine months later.
• Early Phase 3 top-line results for the tumor indication (Tumor-Associated Hyperinsulinism, THI) are imminent.
• Total Addressable Market (TAM) estimated at over $5 billion, combining ~2,000 patients for CHI and ~4,000 for THI.

Business Segments and Product Lines:

• Product: ERSO (ultra-rare disease therapy), a fully human monoclonal antibody targeting refractory hypoglycemia associated with hyperinsulinism.
• Indications: Focused on two segments: Congenital Hyperinsulinism (CHI) and Tumor-Associated Hyperinsulinism (THI), covering insulinomas and Non-Islet Cell Tumor Hypoglycemia (NICTH).
• Regulatory Progress: FDA agreed to a single-arm, open-label Phase 3 study design for the THI indication; Phase 3 for CHI (Sunrise study) faced initial confounding by placebo effects, resolved via Continuous Glucose Monitor (CGM) data showing 50-75% efficacy difference.
• Clinical Data: Expanded Access Program (EAP) treated over a dozen patients with profound outcomes; Phase 3 THI study has 7/8 responders so far.
• Commercial Infrastructure: Planning a lean field team (10-15 salespeople) leveraging machine learning to target concentrated patient pools at pediatric and adult academic centers.

Market and Competitive Landscape:

• Target Population: ~2,000 CHI patients (1,500 diazoxide-responsive with recurrent hypoglycemia + 500 refractory); ~2,500 insulinoma patients and ~1,500 NICTH patients.
• Market Concentration: Patients treated at ~500 pediatric endocrinologists, ~300 insulinoma institutions, and ~65 National Cancer Institute (NCI) centers.
• Pricing Strategy: Ultra-rare disease pricing; weight-based dosing expected to result in high price points (analogous to Ultragenyx's Crisvita), with minimal payer budget impact due to patient scarcity (1-2 patients per payer).
• Competition: No current treatments specifically for NICTH or refractory hypoinsulinism in the tumor setting.

Risks and Challenges:

• Regulatory Risk: Dependence on FDA acceptance of single-arm studies for THI approval; timeline for tumor indication approval remains uncertain pending pre-BLA meeting discussions.
• Clinical/Execution Risk: Prior Phase 3 study (Sunrise) faced significant placebo response confounders; enrollment in ultra-rare disease trials is inherently slow.
• Capital Risk: Current cash reserves ($90M) may not sustain the company through a sequential dual-indication launch without additional financing.
• Market Perception: Disconnect between $5B TAM and sub-$500M market cap, partially attributed to the recent Phase 3 placebo setback.

Management Commentary and Tone:

• Tone: Highly confident and emboldened, citing strong efficacy data, FDA collaboration, and the "sledgehammer effect" of the drug in clinical practice.
• Strategy: Management emphasizes the unmet need, the alignment with FDA on streamlined pathways, and the potential for the drug to enable cancer therapies previously impossible due to hypoglycemia.
• Leadership: CEO Nevin Elam highlighted the company's readiness to file and grow; CCO Sunil Karnavat detailed the commercial roadmap and machine learning-driven patient targeting.

Analyst Questions and Answers:

• Q: Will a single-arm open-label study suffice for FDA approval of the THI indication?
  • A: Yes, the FDA has agreed to this design due to the massive unmet need and clear efficacy observed in the Expanded Access Program.
• Q: How did the FDA react to the Phase 3 CHI placebo issue?
  • A: FDA acknowledged the confounder, accepted CGM data as a superior endpoint, and instructed the company to proceed with the BLA process.
• Q: What is the rationale for a 9-month gap between CHI and THI filings?
  • A: Conservative planning to file CHI first; tumor timeline depends on upcoming pre-BLA discussions, though an accelerated path is possible given the end-of-life nature.
• Q: How will the company fund the commercial launch?
  • A: The balance sheet needs strengthening for a dual launch; management expects significant investor interest given the asset quality.
• Q: Why is the market cap significantly lower than the $5B TAM?
  • A: Market dislocation following the previous Phase 3 placebo event; management believes the gap will close as the drug's power and two-indication potential become evident.

Other Key Points:

• The drug is weight-based, necessitating higher absolute costs for the larger, heavier adult tumor patient population compared to the pediatric CHI population.
• Commercial launch will target specific academic medical centers and NCI facilities where the patient population is concentrated.
• The company is leveraging machine learning to identify and reach the specific physicians treating these ultra-rare conditions.
• Management views the recent FDA interactions as a validation of their data strategy and the drug's value proposition.